Ungerstedt U, Herrera-Marschitz M, Forster C
J Clin Psychiatry. 1985 Apr;46(4 Pt 2):34-7.
The occurrence of tardive dyskinesia has been related to treatment with most typical neuroleptic drugs. It has been hypothesized that risk of the disorder may be less with some atypical antipsychotic agents. Other contributing risk factors may include an underlying vulnerability of the nervous system. Understanding of these features of tardive dyskinesia should be enhanced through more information on functional differences between dopamine receptors and on how different types of antipsychotic drugs affect such receptors. In our animal studies, we have found evidence that dopamine D-1 and D-2 receptors are functionally linked to different behavioral phenomena in the rat, that they are differently affected by dopamine agonist and antagonist drugs, and that they may be selectively localized to different postsynaptic neuronal systems. We suggest that the development of antipsychotic drugs with a low risk of inducing tardive dyskinesia or of novel treatments for this condition may arise from improved understanding of the functions of various dopamine receptors in the brain.
迟发性运动障碍的发生与大多数典型抗精神病药物的治疗有关。据推测，某些非典型抗精神病药物引发该疾病的风险可能较低。其他促成风险因素可能包括神经系统的潜在易损性。通过获取更多关于多巴胺受体之间功能差异以及不同类型抗精神病药物如何影响此类受体的信息，应能增强对迟发性运动障碍这些特征的理解。在我们的动物研究中，我们已发现证据表明，多巴胺D-1和D-2受体在功能上与大鼠的不同行为现象相关联，它们受多巴胺激动剂和拮抗剂药物的影响不同，并且它们可能选择性地定位于不同的突触后神经元系统。我们认为，开发诱发迟发性运动障碍风险低的抗精神病药物或针对这种病症的新疗法，可能源于对大脑中各种多巴胺受体功能的更好理解。
